Posters

Abstracts are in order by last name of the presenting authors.   This PDF file (10.4 MB) has all abstracts in the order below. Alternately, individual abstracts are available by clicking on a title below.

Abstract reviewers are too numerous to mention, but thank you to Dick Brundage for managing the enormous review process of over 200 abstracts, and our poster committee: Paolo Vicini (chair) and members: Narayan Cheruvu, Xiaohua Gong, and Yin Zhan for arranging a thoughtfully organized poster session.  

We request that poster presenters upload a copy of their poster for the ACoP website- these will be posted after the conference.  You may upload your poster HERE.  Posters that are already uploaded will be desigated by a link specifying the file type ("PPT" or "PDF") in the Poster column below.

Name Abstract Authors Poster
Topic
Anson K. Abraham Translation of Parathyroid Hormone Stimulation for the Calcium-sensing Receptor Antagonists from Rats to Humans using a Pharmacokinetic/ Pharmacodynamic Model Anson K. Abraham*, Tristan S. Maurer, Amit Kalgutkar, Xiang Gao, Mei Li, David R. Healy, Donna N. Petersen, David A. Griffith, and Donald E. Mager   PK-PD and mechanistic modeling - Exposure response PK-PD and mechanistic modeling - Translational applications
Sima Ahadieh Model-Based Meta-Analysis of Epworth Sleepiness Scale and Maintenance of Wakefulness Test in Narcolepsy Patients Sima Ahadieh, Thomas Tensfeldt, Yifan Huang, Donna Palumbo, Jing Liu  PPT PK-PD and mechanistic modeling - PD Time course/dose response modeling
Jae Eun Ahn Implementation of the Target-Mediated Drug Disposition Model with a Hypothetical Bound Compartment in Monolix Jae Eun Ahn, Piet Van Der Graaf, Tomomi Matsuura, and Jonathan French   PK-PD and mechanistic modeling - Exposure response
Sihem Ait-Oudhia Pooled Analysis of Four Paclitaxel Delivery Systems using a Unified Pharmacokinetic Model that Provides Insight into Formulation-Dependent Toxicity Sihem Ait-Oudhia*, Robert M Straubinger, and Donald E Mager   Clinical applications: therapeutic areas - Oncology
Guohua An A physiological based pharmacokinetic model of mitoxantrone in mice: a mechanism-based model incorporating DNA and protein binding Guohua An and Marilyn E. Morris   PK-PD and mechanistic modeling - Physiologically-based modeling
Gautam Baheti Population Pharmacokinetic (PK) Modeling of Atazanavir (ATV) in AIDS Clinical Trials Group (ACTG) PEARLS Study G Baheti*, A Andrade, RC Brundage, N Kumarasamy, T Flanigan, J Hakim, K Braun, T Campbell and CV Fletcher  PDF Clinical applications: therapeutic areas - Antiviral and antimicrobial
Gautam Baheti Plasma and Intracellular Population Pharmacokinetics Analysis of Tenofovir in HIV-1 Infected Patients G Baheti, RC Brundage, JJ Kiser, P Havens, CV Fletcher  PDF Clinical applications: therapeutic areas - Antiviral and antimicrobial
Kyle Baron Evaluation of Rapid and Sustained Population Viral Response Rates Predicted Under Hepatitis C Viral Dynamic Models Kyle Baron, Patanjali Ravva, Vivek Purohit, Matthew M. Riggs, Marc R. Gastonguay  PDF PK-PD and mechanistic modeling - Other Clinical applications: therapeutic areas - Antiviral and antimicrobial
Leon Bax Graphical Assessments in Aggregate Level Meta-analysis; an Illustration with Clozapine Data Leon Bax, Karel Moons, Toshihiko Satoh, T.J. Carrothers, Bill Poland  PDF Tools and techniques - Meta-analysis
Timothy Bergsma Systematic Review of Versioned Files for Modeling and Simulation Quality Control: The "review" R Package Timothy Bergsma*, Jeannine Fisher, Marc Gastonguay, Jeffrey Hane, William Knebel, Matthew Riggs, James Rogers  PDF Tools and techniques - Software and algorithms
Timothy Bergsma Strategic Data Handling for Pharmacometrics Timothy Bergsma*, Jeannine Fisher, Marc Gastonguay, Jeffrey Hane, William Knebel, Matthew Riggs, James Rogers  PDF Tools and techniques - Software and algorithms
Julie Bertrand Extensive Population Pharmacokinetic-Pharmacogenetic Study of Nevirapine in HIV-Infected Cambodian Patients Julie Bertrand, Monidarin Chou, Danielle M Richardson, Céline Verstuyft, Paul D Leger, France Mentré, Anne-Marie Taburet, David W Haas, and ANRS 12154 study group  PDF Clinical applications: therapeutic areas - Antiviral and antimicrobial
Julie Bertrand Some Alternatives to Likelihood ratio and Wald Tests for Pharmacogenetic studies using nonlinear mixed effect models Julie Bertrand, Emmanuelle Comets, Marylore Chenel, France Mentré  PDF Tools and techniques - Statistics and biostatistics
Sebastien Bihorel scaRabee: An R package for Model Simulation and Optimization in Pharmacometrics Sebastien Bihorel  PDF Tools and techniques - Software and algorithms
James Bosley Accelerator Mass Spectrometry (AMS) Enables Pediatric PK/PD Analysis in a Neonate Clinical Trial Rebecca Baillie, Toufigh Gordi, James Bosley, Arlin Blood, Herbert Vasquez, Le Vuong   Special populations - Pediatrics
James Bosley Modeling Supports Determination of First-In-Human Dosing and Rapid Titration to Final Dose for Subcutaneous Administration of LIPO-102 Ken Locke, Jim Bosley, Toufigh Gordi, Ron Beaver   Clinical applications: general - Study design/conduct
Jim Bosley Qualifying Mechanistic Physiological Models for Use in Pharmaceutical Discovery and Development Christina M. Friedrich, Jim Bosley, Rebecca Baillie, Ron Beaver   PK-PD and mechanistic modeling - Physiologically-based modeling
Jim Bosley Pharmacokinetic and Pharmacodynamic Modeling and Simulation Support Development of MN-221, a Novel, Highly-Selective Beta2-Adrenergic Agonist for Treatment of Acute Asthma Kazuko Matsuda, Kirk Johnson, Alan Dunton, Maria Feldman, Brian Sadler, James Bosley, Ron Beaver   Clinical applications: general - Study design/conduct
Jim Bosley Pharmacokinetics and Pharmacodynamic Modeling Supports Development of MN-221, a Novel Highly-Selective Beta2-Adrenergic Agonist for Treatment of Acute Exacerbations of COPD Kazuko Matsuda, Kirk Johnson, Alan W. Dunton, Ernest Kitt, Brian Sadler, James Bosley, Ron Beaver   Clinical applications: general - Study design/conduct
Jim Bosley Impact of Modeling on GPR119 Agonist Development David Tess, Avijit Ghosh*, Danny Chen, Peter Cornelius, Tristan Maurer, Rebecca Baillie, Jim Bosley, and Ron Beaver   PK-PD and mechanistic modeling - Physiologically-based modeling
Jurgen B Bulitta Different Approaches to Estimate Covariate Effects with or without Uncertainty in the Covariate Values via the Importance Sampling Expectation Maximization Algorithm Jurgen B Bulitta, Cornelia B Landersdorfer  PDF Tools and techniques - Model building
Wonkyung Byon QUANTITATIVE PK/PD TRANSLATION OF PRECLINICAL BIOMARKER RESPONSE TO CLINICAL PROOF OF MECHANISM (POM) Wonkyung Byon*, Cheng Chang, Yifeng Lu, Aarti Sawant, Leslie Jacobsen, Jing Liu, Sarah Grimwood, Lori Badura, Ellen Wang, Tristan Maurer  PDF PK-PD and mechanistic modeling - Translational applications
Ann Chain Not-In-Trial Simulation: Predicting Cardiovascular Risk from Clinical Trial Data Ann Chain, Jeanne Dieleman, Charlotte van Noord, Meindert Danhof, Miriam Sturkenboom, Bruno Stricker, Oscar Della Pasqua   PK-PD and mechanistic modeling - Translational applications
Anne Chain Generating RR Intervals for the Assessment of Drug Effects in Clinical Trial Simulations Anne Chain, Francesco Bellanti, Meindert Danhof, Oscar Della Pasqua   Clinical applications: general - Study design/conduct
Hui Min Chan Inception of an HCV Platform Model for IL-28B Genotype Treatment Duration Optimization and Cure Rate Maximization Hui Min Chan, Xiaodong Wang, Nelson Jumbe, Russell Wada, Alaa Ahmad, Vikram Kansra  PPT Clinical applications: therapeutic areas - Antiviral and antimicrobial
Jenny Y. Chien Time Course Models for Long Term Treatment of Type II Diabetes Mellitus with Oral Medications Jessica C. Tay, Parag Garhyan*, Jeanne S. Geiser, Jenny Y. Chien, Vikram P. Sinha   PK-PD and mechanistic modeling - Translational applications
Jenny Y. Chien Comparison of predictive performance of empirical and mechanistic time-course models of HbA1c from fasting glucose Parag Garhyan*, Xin Zhang, Jessica C. Tay, Jeanne S. Geiser, Xiaosu Ma, Jenny Y. Chien, Vikram P. Sinha   PK-PD and mechanistic modeling - Translational applications
Jason Chittenden Estimating a Time-Variant Pharmacokinetic Parameter as a Random Process Jason Chittenden  PDF Tools and techniques - Model building
Joannellyn Chiu Aggregation, Modeling and Prediction of HIV Antiviral Efficacy Data from the Last 10 Years of Published Clinical Trials (Amply)-Part II: Meta-Data Analysis of Full Time Course Response Rates Joannellyn Chiu, Xiaohua Gong, Mark Lovern, Roberto Gomeni  PPT Tools and techniques - Meta-analysis
Willem de Winter A Mechanism-Based Population Model for Body Weight Change in Clinical Populations Willem de Winter   PK-PD and mechanistic modeling - Systems biology
William S. Denney Model-Based Meta-Analysis of HbA1c, Weight, and FPG in Type 2 Diabetes: Focus on SGLT2 inhibitors William S. Denney* and Gianluca Nucci  PPT PK-PD and mechanistic modeling - Exposure response Clinical applications: therapeutic areas - Diabetes
Amit Desai THE EFFECTS OF CAFFEINE ON REGADENSOSN EXPOSURE RESPONSE RELATIONSHIP Amit Desai*, Robert Townsend, Bruce McNutt, Atsunori Kaibara   PK-PD and mechanistic modeling - Exposure response
Tuan Dinh A Mathematical Model of Health and Economic Outcomes of Colon Cancer Treatment Tuan Dinh, Peter Alperin PDF Clinical applications: therapeutic areas - Oncology Clinical applications: general - Disease models
Sameer Doshi Denosumab Dose Selection for Preventing Skeletal Related Events in Patients with Solid Tumors Sameer Doshi*, Liviawati Sutjandra, Jenny Zheng, Winnie Sohn, Mark Peterson, Graham Jang, Andrew Chow, Juan Jose Perez Ruixo   PK-PD and mechanistic modeling - Exposure response
Anne Dubois Pharmacokinetic Bioequivalence Analysis of Biologics Using Nonlinear Mixed Effects Modeling Anne Dubois, Sandro Gsteiger, Sigrid Balser, Etienne Pigeolet, Jean-Louis Steimer, Goonaseelan Pillai and France Mentré  PDF Tools and techniques - Statistics and biostatistics
Farkad Ezzet Literature Data Survival Models: Case Studies for Anticoagulants in Atrial Fibrillation and Acute Coronary Syndrome Farkad Ezzet  PPT Tools and techniques - Meta-analysis
Demiana Faltaos Quantification of Disease Progression and Drop-Out for Alzheimer's Disease Demiana Faltaos*, Ying Chen, Weihua Hao, Peter Lee, Jogarao Gobburu, Yaning Wang, Hao Zhu  PDF Clinical applications: therapeutic areas - Neurodegenerative diseases
Yan Feng Characterization of Ipilimumab Exposure-Efficacy/Safety Response Relationships in Advanced Melanoma Patients Yan Feng*, Eric Masson, David Berman, Susan M. Parker, Axel Hoos, Tai-Tsang Chen, Marc Pfister, and Amit Roy   Clinical applications: therapeutic areas - Oncology
Frédérique Fenneteau Rational Drug Delineation: A Global Sensitivity Approach based on Therapeutic Tolerability to Deviations in Execution Denis Goue Gohore, Frédérique Fenneteau*, Olivier Barriere, Jun Li, Fahima Nekka   PK-PD and mechanistic modeling - Other
Immanuel Freedman Case Study – Bridging from Western to East Asian Population in Accordance with ICH E5 Immanuel Freedman  PDF Special populations - Ethnicity
Lena E Friberg Integrated Population Pharmacokinetics of Voriconazole in Children, Adolescents and Adults Lena E Friberg, Patanjali Ravva, Mats O Karlsson, Ping Liu  PDF Special populations - Pediatrics Clinical applications: therapeutic areas - Antiviral and antimicrobial
Jianjun Gan Aggregation, Modeling and Prediction of HIV Antiviral Efficacy Data from the Last 10 Years of Published Clinical Trials (AMPLY) - Part III: A Bayesian Prediction Model of Long Term Response Rate by HIV Drug Class and Patient Population Jianjun Gan* , Shuguang Chen , Joannellyn Chiu, Xiaohua Gong , Mark Lovern , Yu Lou  PDF Tools and techniques - Meta-analysis
Yuying Gao A Population Pharmacokinetic Analysis of Dalfampridine Extended Release Tablets in Healthy Volunteers and Multiple Sclerosis Patients Yuying Gao*, Lawrence Marinucci, Susan L Way, Herbert R Henney III, Russell Wada  PDF PK-PD and mechanistic modeling - Physiologically-based modeling
Tushar Garimella Meta-Analyses of Adverse Events and Dropout in Diabetic Neuropathic Pain Trials Tushar Garimella , Ahmed A. Othman , Sandeep Dutta, Walid M. Awni and Jaap W. Mandema.  PDF Tools and techniques - Meta-analysis
Samira Merali Garonzik Mechanism Based Model for the Inoculum Effect of Vancomycin against Methicillin Resistant Staphylococcus aureus. Samira Merali Garonzik* , Jurgen B. Bulitta, Brian T. Tsuji, Patricia N. Holden, Alan Forrest  PDF PK-PD and mechanistic modeling - Translational applications
Marc R. Gastonguay A Population Pharmacokinetic Model of Tacrolimus in Pediatric Liver Transplant Recipients Georgina Cirrincione-Dall*, Marc R. Gastonguay, William Knebel, Timothy Bergsma, A. Yin Zhang, Dimple Patel, Jeffrey S. Barrett, Ron van Schaik, Offie P. Soldin, Steve J. Soldin, Irena Nulman, Gideon Koren, Saskia N de Wildt
  PDF Special populations - Pediatrics Special populations - Other (Transplant)
Francois Gaudreault SEMI-MECHANISTIC POPULATION PHARMACOKINETIC MODEL OF ROPIVACAINE AFTER FEMORAL NERVE BLOCK IN PATIENTS UNDERGOING KNEE SURGERY Francois Gaudreault*, Jun Li, Pierre Drolet, France Varin.  PPT Clinical applications: general - Clinical pharmacokinetics
Jeanne Geiser A Sequential Statistical and Population Pharmacodynamic Approach to Assess the Effects of the Genetic Polymorphisms as Predictors of Efficacy for a Novel Antihyperglycemic Agent Jeanne Geiser, Yanni Zhu, Jenny Chien   Clinical applications: therapeutic areas - Diabetes
Parviz Ghahramani Pharmacokinetic Evaluation of Dosing Regimen Switch from 10 mg Twice Daily Memantine Immediate Release Tablet to 28 mg Once Daily Extended-Release Capsule Using a Simulation Approach Antonia Periclou, Parviz Ghahramani   PK-PD and mechanistic modeling - Other PK simulation supporting formulation switch for regulatory approvals
Avijit Ghosh A Minimal Systems Pharmacology Model of SGLT2/SGLT1 Glucose Uptake and Transport with Applications to SGLT2 inhibition N. Haddish Berhane , G. Nucci , A. Sawant, T. Maurer, A. Ghosh*   PK-PD and mechanistic modeling - Systems biology Clinical applications: therapeutic areas - Diabetes
Nagdeep Giri A Population Analysis of the Relationship Between QTcS and PF-00299804 Plasma Concentrations for PF-00299804 Using Data from Four Clinical Trials in Patients with Advanced Cancer. Nagdeep Giri*, Diana Gernhardt, Emiko Ohki, Stephen Letrent, Carlo Bello, Ana Ruiz  PDF PK-PD and mechanistic modeling - Exposure response Special populations - Other (Advanced cancer patients)
Xiaohua Gong Aggregation, Modeling and Prediction of HIV Antiviral Clinical Efficacy Data from Last 10 Years of Published Clinical Trials (AMPLY)-Part I: Aggregation Strategy and Implementation Xiaohua Gong, Mark Lovern, Roberto Gomeni  PDF Tools and techniques - Meta-analysis
Navinkumar Goyal An Integrated Metric to Assess the Clinical Utility of a Drug in Presence of Efficacy and Dropout Information Navinkumar Goyal, Roberto Gomeni   Clinical applications: general - Benefit-risk assessment
Navinkumar Goyal A Latent Variable Approach for Characterizing the Informative Dropout Process Navinkumar Goyal, Roberto Gomeni  PDF Tools and techniques - Missing data
M. Green Use of Model Based Meta-Analysis Combining Patient-Level with Summary-Level Data Using Multilevel Random Effects to Provide a Quantitative Assessment of the Clinical Efficacy (IPSS) Profile and Competitive Positioning of a PDE5 Inhibitor (UK369,003) N.H. Prins, M. Green* , S. Haughie, P. Johnson, S.W. Martin  PDF PK-PD and mechanistic modeling - Exposure response Tools and techniques - Meta-analysis
Manish Gupta Exposure-Response Analysis in Patients with HER2-positive (HER2+) Metastatic Breast Cancer (MBC) to Assess the Effect of T-DM1 on QTc Prolongation Manish Gupta*, Bei Wang, TJ Carrothers, Amita Joshi, Patricia M LoRusso, Wayne Chu, Ted Shih, David Loecke, Sandhya Girish   PK-PD and mechanistic modeling - Exposure response
Serge Guzy Quantitative analysis of bioanalytical assay precision using mixed-effect modeling: A new method applied to pre validation assay data Serge Guzy, Jeremy Ma, Milan Tomic   Tools and techniques - Statistics and biostatistics
Serge Guzy OPTIMIZING THE ENTIRE DRUG DEVELOPMENT PROCESS USING PHARMACOMETRIC TOOLS: FROM PRECLINICAL TO MARKETING Serge Guzy   PK-PD and mechanistic modeling - Exposure response
Yaming Hang A simulation study to evaluate Normalized Prediction Distribution Error (NPDE) as an internal validation method for population PK models Zifang Guo, Yaming Hang, Huafeng Zhou, Kuenhi Tsai  PPT Tools and techniques - Model evaluation
Emma K. Hansson PKPD Modeling of VEGF, sVEGFR-2, sVEGFR-3 and sKIT as Biomarkers of Tumor Response Following Sunitinib Treatment in GIST Emma K. Hansson, Paul Westwood, Michael Amantea, Peter A. Milligan, Mats O. Karlsson, Lena E. Friberg  PDF Clinical applications: therapeutic areas - Oncology
Chihiro Hasegawa Performance of NONMEM 7 Estimation Methods for Continuous Time Markov Model Chihiro Hasegawa  PDF Tools and techniques - Non-continuous data
Michael Heathman A Joint Model for Nausea, Vomiting, and Dropouts to Design a Tolerability-based Dose Titration Regimen Michael Heathman and Jenny Chien  PDF Tools and techniques - Non-continuous data
Lee Hodge Value of Information: Embedding the Power of Modeling and Simulation into Strategic Decisions Hodge, Lee; Dykstra, Kevin  PDF Tools and techniques - Decision Analysis Clinical applications: general - Study design/conduct
Joy C. Hsu Two Empirical Models to Handle Transient Time-Dependency Joy C. Hsu, Nicolas Frey, Valerie Cosson   Tools and techniques - Model building Clinical applications: general - Clinical pharmacokinetics
Xiao Hu Development of PK/PD Models for PEGylated-Interferon Beta-1a Xiao Hu, Ivan Nestorov  PPT PK-PD and mechanistic modeling - Exposure response
Kaori Ito Modeling of Functional Assessment Questionnaire (FAQ) as Continuous Bounded Data from the Alzheimer's Disease Neuroimaging Initiative (ADNI) Database Kaori Ito, Matt Hutmacher, Brian Corrigan  PDF Clinical applications: general - Disease models
Masoud Jamei Modelling the Effect of Interleukin-6, an Inflammatory Cytokine, on Time-dependent Reduction of Cyclosporine Clearance: An Application of the Simcyp Population-based Simulator to Suppression of CYP450 by Biologics Krishna K Machavaram, Lisa M Almond, Masoud Jamei and Amin Rostami-Hodjegan  PDF PK-PD and mechanistic modeling - Physiologically-based modeling PK-PD and mechanistic modeling - Translational applications
Juif (Frank) Jen Modeling and Simulations in Designing a Cardiovascular Trial Juif (Frank) Jen*, Harry Shi, Ching-Ray Yu, John Vincent, Bimal Malhotra, and Kuan Gandelman   Clinical applications: therapeutic areas - Heart failure
Feng Jin Mechanism-based Pharmacokinetic and Pharmacodynamic Modeling of MEDI-575, a Monoclonal Antibody Directed against PDGFRalpha, in Cynomolgus Monkeys Feng Jin, Meina Liang, Bing Wang, Inna Vainshtein, Amy Schneider, Carlos Chavez, Brandon Lam, Raffaella Faggioni, and Lorin Roskos  PDF PK-PD and mechanistic modeling - Translational applications
Jin Y. Jin Application of Mechanism-Based Modeling and Simulation to Understand the Atypical Nonlinear Pharmacokinetics of a Novel Hedgehog Pathway Inhibitor GDC-0449 Jin Y. Jin*, Richard A. Graham, Sravanthi Cheeti, Karin Jorga, Bert L. Lum, Josina C. Reddy, Jennifer A. Low, Frank-Peter Theil, Mark Dresser, and Amita Joshi  PDF Clinical applications: therapeutic areas - Oncology Clinical applications: general - Clinical pharmacokinetics
Jin Y. Jin Population Pharmacokinetic and Pharmacodynamic Modeling of the Dual PI3K/mTOR Inhibitor GDC-0980 in Phase I Oncology Patients Jin Y. Jin*, Joseph Ware, Hanbin Li, Vikram Malhi, Jenny Wu, Yibing Yan, Jennifer Lauchle, Scott Holden, Mika Derynck, and Mark Dresser   PK-PD and mechanistic modeling - Exposure response Clinical applications: therapeutic areas - Oncology
Jin Y. Jin Population Pharmacokinetic Modeling of MEK Inhibitor GDC-0973 in Phase I Oncology Patients Nageshwar Budha, Luna Musib, Steve Eppler, Joseph Ware, Iris Chan, Mark Dresser, and Jin Y. Jin*   Clinical applications: therapeutic areas - Oncology Clinical applications: general - Clinical pharmacokinetics
Jin Y. Jin Application of Pharmacokinetic/Pharmacodynamic Modeling and Simulation to Optimize Dosing Strategy for Combination Therapy in Oncology Phase Ib Jin Y. Jin*, Nageshwar Budha, Edna Choo, Laurent Salphati, Luna Musib, Joseph Ware, Steve Eppler, Iris Chan, and Mark Dresser  PDF PK-PD and mechanistic modeling - Translational applications Clinical applications: therapeutic areas - Oncology
Jin Y. Jin Application of WinPOPT to Optimize Trial Design for Single Agent or Combination Therapy in Oncology Phase Ib and Phase II Jin Y. Jin*, Shubhra Upadhyay, Nageshwar Budha, Yanan Zheng, Joseph Ware, and Mark Dresser  PDF Tools and techniques - Experiment design Clinical applications: therapeutic areas - Oncology
Yuyan Jin Impact of Various Clinical Practice Strategies on Cardiovascular Risk for the Treatment of Hypertension: A Clinical Trial Simulation Study Yuyan Jin*, Robert Bies, Marc Gastonguay, Norman Stockbridge, Jogarao Gobburu, Rajnikanth Madabushi  PDF Clinical applications: Hypertesion, Cardiovascular Risk, Public Health
Martin Johnson Mechanism Based Pharmacokinetic and Pharmacodynamic Modeling of Dopamine D2 Receptor Occupancy in Rats and its Application in Translational Modeling Martin Johnson, Magdalena Kozielska, Venkatesh Pilla Reddy,An Vermeulen,Hugh Barton,Sarah Grimwood, Rik de Greef, Geny M.M.Groothuis,Meindert Danhof,Johannes H.Proost  PDF PK-PD and mechanistic modeling - Translational applications
Daniël M. Jonker Population Pharmacokinetics In Phase 3 – A Delicate Balance Between Exploration And Confirmation Of Covariate Effects Daniël M. Jonker, Steen H. Ingwersen, Christoffer Tornøe  PDF Tools and techniques - Model building Tools and techniques - Model evaluation
NL Shasha Jumbe Dose Selection Analysis for Pixantrone Dimaleate (BBR 2778) for the Treatment of Patients with Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma NL Shasha Jumbe, D Russell Wada, Gabor Jurida, Jack W Singer, Lixia Wang  PDF PK-PD and mechanistic modeling - Exposure response Clinical applications: therapeutic areas - Oncology
Nele Kaessner Population Pharmacokinetic Metaanalysis for Instanyl® – an intranasal fentanyl spray (INFS) for breakthrough pain in patients with cancer Nele Kaessner, Ruediger Nave, Stefan Roepcke, Axel Facius, Gezim Lahu  PDF Clinical applications: general - Clinical pharmacokinetics
Nitin Kaila An Approach to Modeling and Simulation of Pediatric Drug Exposure Based on Adult Population Pharmacokinetics (PopPK) Nitin Kaila*, Wenping Wang, Thomas Bouillon, William Ebling, Ramesh Sarangapani, YanLing He, Phillip DK Lee   PK-PD and mechanistic modeling - Exposure response Special populations - Pediatrics
Mohamed Kamal Identification of New Oral Dose Regimens for the Neuraminidase Inhibitor Oseltamivir (Tamiflu®) in Patients with Moderate and Severe Renal Impairment Supported by a Population Pharmacokinetic Approach Mohamed Kamal*, Barbara Brennan, Vishak Subramoney, Peter N Morcos, Nicolas Frey, Craig Rayner  PPT Special populations - Renal or hepatic impairment
Nastya Kassir An Optimal Sampling Strategy for Tacrolimus in Pediatric Liver Transplant Recipients Based on a Population Pharmacokinetic Model Nastya Kassir, Jean-Romain Delaloye, Mohamad-Samer Mouksassi, Anne-Laure Lapeyraque, Line Labbé, Fernando Alvarez, Michel Lallier, Mona Beaunoyer, Yves Théorêt, Catherine Litalien  PDF Special populations - Pediatrics
Ron Keizer Performance of Methods for Handling Missing Categorical Covariate Data in Population Pharmacokinetic Analyses Ron Keizer, Anthe Zandvliet, Jos Beijnen, Jan Schellens, Alwin Huitema  PDF Tools and techniques - Model building Tools and techniques - Missing data Covariates
Thomas Kerbusch Phase 2b dose selection for the treatment of autoimmune disorders leveraging comparator data Thomas Kerbusch, Russ Wada, Anthe Zandvliet, Kuenhi Tsai, Jing Su, Joanna Zhuoying Peng, Yaming Hang, Christine Xu, Richard Shames, Ann Horowitz, Diane Neiman, Mani Lakshminarayanan, Usha Barai, Ferdous Gheyas, Paul Peloso, Devan Mehrotra, Nancy Zhang, Hanbin Li, Jaap Mandema, Gary Herman, Sandy Allerheiligen   Clinical applications: general - Study design/conduct
Kiana Keyvanjah Improved dosing guidelines, of epsilon-aminocaproic acid (EACA), in neonates undergoing cardiac surgery involving cardiopulmonary bypass (CPB) Kiana Keyvanjah, Michael Eaton, Curt Haas, Alan Forrest   Special populations - Pediatrics
Kiana Keyvanjah Mechanism-Based Model for the Pharmacodynamics (PD) of Daptomycin Characterizing High Inoculum Data, Implications for High Bacterial Burden. Kiana Keyvanjah*, Samira M. Garonzik, Alan Forrest  PDF Clinical applications: therapeutic areas - Antiviral and antimicrobial
Hyewon Kim A Population Analysis of Time-to-Event Pharmacodynamic Responses: The Effect of Ranitidine on Gastric Acid Secretion Hyewon Kim, Henry J. Mann, Richard C. Brundage   PK-PD and mechanistic modeling - Exposure response
Hyewon Kim The Simultaneous and Sequential Pharmacokinetic-Pharmacodynamic Models of Ranitidine in Critically Ill Patients and Healthy Volunteers Hyewon Kim, Henry J. Mann, Richard C. Brundage   PK-PD and mechanistic modeling - Exposure response
Holly Kimko Population Disease-Drug Model of Methylphenidate in Children with Attention Deficit Hyperactivity Disorder Via Model-Based Meta-analysis Holly Kimko, Ekaterina Gibiansky, Leonid Gibiansky, H. Lynn Starr, Joris Berwaerts, Joseph Massarella, Robert Armstrong, Frank Wiegand  PDF Tools and techniques - Meta-analysis Special populations - Pediatrics
Holly Kimko A Simulation Study to Assess the Impact of Low Frequency of Data below the Quantification Limit on Pharmacokinetic Parameter Estimates Xu Steven Xu, Adrian Dunne, Holly Kimko, Partha Nandy, and An Vermeulen  PPT Tools and techniques - Missing data
Mita Kuchimanchi Population Pharmacokinetic Modeling of AMG 386 in Phase 2 Ovarian Cancer Patients Mita Kuchimanchi, Jian-Feng Lu, Rebeca Melara, and Yu-Nien Sun   Population PK ovarian cancer
Vikas Kumar Development of an Integrated Population Pharmacokinetic Model for Immediate Release and Controlled Release Formulations of an Investigational Compound in Healthy Subjects and Schizophrenia Patients. Vikas Kumar, Kevin Sweeney, Diane Mould, Jing Liu  PPT Population PK, Schizophrenia
Mallika Lala Population Pharmacokinetic-Pharmacogenetic Analysis of Nevirapine in HIV-infected patients in Uganda and the U.S. – A Covariate Exploration Mallika Lala, Konstantina Vanevski, Jogarao Gobburu, Geoffrey Kabuye, Peter Mugyenyi, Ven Natarajan, Raul Alfaro, Henry Masur, Juan Lertora, Scott Penzak   PK-PD and mechanistic modeling - Other Clinical applications: therapeutic areas - Antiviral and antimicrobial Population Pharmacokinetics-Pharmacogenetics
Mallika Lala Covariate models – Do not center at values outside the data range Mallika Lala, Jogarao Gobburu, Yaning Wang   Tools and techniques - Model building Tools and techniques - Statistics and biostatistics
Mallika Lala Implementation of a Pharmacokinetic Quality Standard to Improve Pediatric Trial Design Mallika Lala, Yaning Wang, Pravin Jadhav, Jogarao Gobburu   Special populations - Pediatrics Clinical applications: general - Study design/conduct
Cornelia B. Landersdorfer Mechanism-based Modeling of Antimicrobial Combinations to Efficiently Characterize and Quantify Subpopulation Synergy Cornelia B. Landersdorfer, Neang S. Ly, Brian T. Tsuji, Jurgen B. Bulitta   PK-PD and mechanistic modeling - Translational applications
Grant Langdon Population Pharmacokinetic Modeling of PH-797804 to Aid Dose Selection in patients with Chronic Obstructive Pulmonary Disease (COPD) Yuying Gao, Eugéne Cox, Grant Langdon   Clinical applications: general - Clinical pharmacokinetics
Marc Lavielle Improved diagnostic plots require improved statistic tools Marc Lavielle, Hector Mesa  PDF Tools and techniques - Model evaluation
Marc Lavielle Mixture models and model mixtures with MONOLIX Marc Lavielle, Hector Mesa, Kaelig Chatel , An Vermeulen  PDF Tools and techniques - Model building
Robert H. Leary QRPEM, A Quasi-random Parametric EM Method for PK/PD NLME Estimation Robert H. Leary and Michael Dunlavey  PPT Tools and techniques - Software and algorithms
Jongtae Lee Population pharmacokinetic-pharmacodynamic analysis to assess food effect on PK and PD of fimasartan in healthy male subjects Jongtae Lee*(1), Sangil Jeon(1), Seunghoon Han(1,2), Dong-Seok Yim(1,2)  PPT PK-PD and mechanistic modeling - Exposure response
Micha Levi Mechanistic Viral Kinetic (VK) modeling of a triple therapy for Hepatitis C: a protease inhibitor (Danoprevir) in combination with Pegasys® (PEG-IFN alpha-2a ) and Copegus® (Ribavirin) Micha Levi, Nicolas Frey, Annabelle Lemenuel, Pascal Chanu  PDF PK-PD and mechanistic modeling - Physiologically-based modeling Clinical applications: therapeutic areas - Antiviral and antimicrobial
Fang Li Automated Population PK Reporting Fang Li, Anshu Marathe, Nitin Mehrotra, Jeffry Florian, Ider Lee, Christoffer Tornoe  PDF Tools and techniques - Model evaluation
Hong Li Population Modeling of Long-Term Steroid-induced Bone Loss in Patients Undergoing Hematopoietic Stem Cell Transplantation Hong Li, Claudia M.S. Schulte, Theresa Hahn, Philip L. McCarthy, and Donald E. Mager   PK-PD and mechanistic modeling - Exposure response PK-PD and mechanistic modeling - Systems biology
Lang Li A Semi-PBPK Midazolam-Ketoconazole Interaction Model and Its Identifiability Evaluation Chien-Wei Chiang, Seongho Kim, Sara K. Quinney, and Lang Li   Tools and techniques - Model building Tools and techniques - Model evaluation Tools and techniques - Statistics and biostatistics
Lang Li Paroxetine Auto-Inhibition Pharmacokinetic Modeling Xu Han*(1), Sara Quinney, David A. Flockhart, and Lang Li   PK-PD and mechanistic modeling - Physiologically-based modeling
Hyeong-Seok Lim Exploration of Optimal Dosage Regimen of Vancomycin in Patients with Staphylococcal Infection by Pharmacokinetic and Pharmacodynamic Modeling and Simulation Hyeong-Seok Lim, Yong Pil chong, Jin-ah Jung, Seokjoon Jin, Yook Hwan Noh, Yang Soo Kim   PK-PD and mechanistic modeling - Translational applications
Hyeong-Seok Lim Use of Modeling and Simulation in the Early Clinical Development of a Novel Oral Paclitaxel, DHP107 Hyeong-Seok Lim, Seokjoon Jin, Jin-ah Jung, Ae-Kyung Hwang, Kyun-Seop Bae, Hyeyoun Kim, Yong Sang Hong, Kyo Pyo Kim, Jae-Lyun Lee, Min Hee Ryu, Heung Moon Chang, Yoon-Koo Kang, Tae Won Kim   Clinical applications: therapeutic areas - Oncology
Hyeong-Seok Lim Implications of body weight and body mass index in the pharmacokinetics of letrozole Seokjoon Jin   Clinical applications: general - Clinical pharmacokinetics
Jörg Lippert A coupled PBPK-model of tamoxifen and its three main metabolites to investigate the influence of CYP2D6 polymorphism on endoxifen formation Kristin Dickschen, Thomas Eissing, Stefan Willmann, Georg Hempel, Jörg Lippert   PK-PD and mechanistic modeling - Physiologically-based modeling
Jörg Lippert Predicting study outcome of cancer therapies: Translating in-vitro information to an in-vivo prediction by integration into a full mechanistic PBPK/PD model Michael Block, Katja Tummler, Michaela Meyer, Jörg Lippert   PK-PD and mechanistic modeling - Physiologically-based modeling PK-PD and mechanistic modeling - Systems biology
Dan Lu AN INTEGRATED POPULATION PHARMACOKINETIC MODEL FOR A FIRST-IN-CLASS HER2 TARGETED ANTIBODY-DRUG CONJUGATE TRASTUZUMAB-DM1 (T-DM1): MODELING OF T-DM1 AND TOTAL TRASTUZUMAB PHARMACOKINETICS IN HEAVILY PRETREATED HER2+ METASTATIC BREAST CANCER PATIENTS Dan Lu, Manish Gupta, Bei Wang, Amita Joshi, Frank-Peter Theil, Ian Krop, H.A. Burris, Joo-Hee Yi, Sandhya Girish   PK-PD and mechanistic modeling - Other
Zheng Lu Preclinical pharmacokinetic – pharmacodynamic modeling of neutropenia in cancer therapy and its application in clinical development Zheng Lu*, Frank Lee, WenChyi Shyu   PK-PD and mechanistic modeling - Translational applications
Man Luo Resistance Profile Analysis of an Anti-viral Agent by Mapping Genotypes with Phenotypes Man Luo, Mark Lovern, Mark Underwood, Cindy Vavro, Ivy Song   Tools and techniques - Model building
Jean Francois Marier Application of Trial Simulations to Support Optimal Dosing of Intravenous Acetaminophen in Pediatric Patients: Regulatory Approval of the Product Based on a Minimum Number of Patients. Jean Francois Marier, Mohamad-Samer Mouksassi, Nathalie H Gosselin, J Breitmeyer, M Royal   Special populations - Pediatrics Pain
Jean Francois Marier Population PK/PD Modeling and Simulations of a Fixed-Dose Combination of CXA 101 and Tazobactam to Optimize Dosing Strategies in Renal Impaired Patients With Complicated Urinary Tract Infection Frederique Fenneteau, Nastya Kassir, Mohammad-Samer Mouksassi*, Henri Merdjan, Jean Francois Marier Ellie Hershberger, David Benziger.  PDF PK-PD and mechanistic modeling - Exposure response Clinical applications: therapeutic areas - Antiviral and antimicrobial
Scott Marshall Developing quantitative decision rules for novel analgesic drugs: A case study illustrating current experiences and learnings Scott Marshall*(1), Simon Kirby(1), Anna Crossland(1), Paul Sanders(1), Joe Picard(2), and Bernadette Hughes(1).  PPT Clinical applications: general - Study design/conduct
Robin D. McDougall A Generic Strategy for Tissue-Specific Individualized Drug Delivery using Physiologically-based Pharmacokinetic Models and Adaptive Control Techniques Robin D. McDougall*, Conrad J. Housand, and Ruth Milman   PK-PD and mechanistic modeling - Physiologically-based modeling Clinical applications: therapeutic areas - Other therapeutic area
Lynn McFadyen Modeling of Maraviroc Pharmacokinetics in the Presence of Atazanavir/Ritonavir in Healthy Volunteers and HIV-1 Infected Patients Barry Weatherley, Manoli Vourvahis, Lynn McFadyen*   Clinical applications: therapeutic areas - Antiviral and antimicrobial
France Mentré New features for population design evaluation and optimisation with R functions: PFIM Interface 3.1 and PFIM 3.2 Caroline Bazzoli, Thu-Thuy Nguyen, Emanuelle Comets, Anne Dubois, Hervé Le Nagard, France Mentré*  PDF Tools and techniques - Experiment design
France Mentré Comparison of results of the different software for design evaluation in population pharmacokinetics and pharmacodynamics. France Mentré*, Joakim Nyberg, Kay Ogungbenro, Sergei Leonov, Alexander Aliev, Stephen Duffull, Caroline Bazzoli, Andrew C. Hooker  PDF Tools and techniques - Experiment design
Katy Moore Use of a Large Biological Model with Single-Dose Clinical Data to Predict Hemoglobin (Hb) Response in Patients with Anemia Katy Moore, Rukmini Kumar, Jianping Zhang, Vincent Hurez, Sirid Kellermann, Connie Erickson-Miller, Rich Brigandi  PDF PK-PD and mechanistic modeling - Systems biology
Samer Mouksassi Streamlining Pharmacometric Analyses Utilizing Multiple Data Management and Modeling Tools Samer Mouksassi, Martin Beliveau , Erin Guinan, Helen Moore, Roberto Gomeni, Xiaobin Li, Oscar Della Pasqua, Daniel Weiner, Frank Hoke   Tools and techniques - Software and algorithms
Mohamad-Samer Mouksassi Cluster Analyses, Logistic Regressions, and Receiver Operator Characteristics (ROC) to Complement PK/PD Modeling: Case Studies for Immunomodulator, Anti-Depressive, and Anti-Diabetes Products Mohamad-Samer Mouksassi*, Nathalie H Gosselin, Nastya Kassir, Frederique Fenneteau, Benjamin Rich, and Jean Francois Marier   Tools and techniques - Non-continuous data Clinical applications: general - Clinical outcomes
Mohamad-Samer Mouksassi A Novel GAMLSS Model to Facilitate Simulations of Demographic Covariates in Special Populations: Selection of Realistic Covariates in Pediatric and Geriatric Patients in Clinical Trial Simulations to Optimize Dosing Mohamad-Samer Mouksassi* , Nathalie H Gosselin ,Nastya Kassir, Frederique Fenneteau, Benjamin Rich, and Jean Francois Marier   Special populations - Geriatrics Special populations - Pediatrics
Runa Naik Pharmacokinetic Drug-Drug Interaction for Biologics: Modeling & Simulation Based Approach Runa Naik, Nageshwar Budha, Russell Wada3, Manish Gupta   PK-PD and mechanistic modeling - Exposure response
Srividya Neelakantan Joint Model-based Meta-Analysis of Longitudinal FPG and HbA1c Responses for GLP-1Analogues and DPP-4 Inhibitors Srividya Neelakantan* , Danny Chen, Kevin Sweeney   Clinical applications: therapeutic areas - Diabetes
Michael Neely Zidovudine Glucuronidation in Premature and Term Infants Michael Neely*, Andrea Kovacs, Mark Mirochnick, Edmund Capparelli  PDF Special populations - Pediatrics Clinical applications: therapeutic areas - Antiviral and antimicrobial
Fahima Nekka A Bayesian Decision Approach to Retrace the Patient Compliance Based on limited Sampling Information Olivier Barrière, Jun Li, Fahima Nekka  PDF PK-PD and mechanistic modeling - Compliance and inverse problem
Chee M Ng Novel GPU Parallelization of Monte-Carlo Parametric Expectation Maximization Estimation Algorithm for Population Data Analysis Chee M Ng   Tools and techniques - Software and algorithms
Anne Q.N. Nguyen EVIDENCE OF A CONCENTRATION-EFFECT RELATIONSHIP FOR INHALED MILRINONE USING POOLED DATA FROM PULMONARY HYPERTENSIVE PATIENTS UNDERGOING CARDIAC SURGERY Anne Q.N. Nguyen*, André Y. Denault, Louis P. Perrault, France Varin  PDF Clinical applications: general - Clinical pharmacokinetics 
Dana Nickens A Systematic Review and Meta-analysis of Recent Drug Therapies for Chemo-naïve Patients with Advanced Pancreatic Cancer Dana Nickens, Reza Khosravan, Michael Amantea, Jonathan French  PDF Tools and techniques - Meta-analysis Clinical applications: therapeutic areas - Oncology
Elisabet I Nielsen PK/PD Indices of Antibiotics Predicted by Semi-Mechanistic PKPD Models – a Step towards Model-Based Dose Optimization Elisabet I Nielsen, Otto Cars, Lena E Friberg  PDF PK-PD and mechanistic modeling - Exposure response Clinical applications: therapeutic areas - Antiviral and antimicrobial
Kenji Nozawa Population pharmacokinetic analysis using a stratified bootstrap method implemented in Phoenix NLME to detect drug interactions Kenji Nozawa, Hitoshi Sato   Tools and techniques - Software and algorithms
Gianluca Nucci Quantitative Human Pharmacology Modeling to Accelerate SGLT2i Drug Development Gianluca Nucci, Avijit Ghosh, Nahor Haddish-Berhane, Paul DaSilva-Jardine, Jeff Trimmer, Mike Reed and Cynthia J Musante  PDF PK-PD and mechanistic modeling - Systems biology
Olanrewaju O. Okusanya SADAPTPlot – An Easy-to-Use R Package for S-ADAPT Population Analysis Post-Processing Olanrewaju O. Okusanya, Jeffery Hamel, Christopher M. Rubino   Tools and techniques - Software and algorithms
Ahmed A. Othman Non-Linear Mixed-Effects Model-Based Meta-Analyses of the Efficacy at End-of-Trials for Drugs Evaluated for Treatment of Diabetic Neuropathic Pain Ahmed A. Othman, Tushar Garimella, Sandeep Dutta, Walid M. Awni, and Jaap W. Mandema  PDF Tools and techniques - Meta-analysis
Rune Overgaard Disease model of the synovium in Rheumatoid Arthritis. Is it a relevant contribution to Phase 2 design? Rune Overgaard, Rene Hansen, Ulrik Mouritzen  PDF PK-PD and mechanistic modeling - Translational applications Clinical applications: therapeutic areas - Immune system
Ridhi Parasrampuria Development of a Mechanism-Based Model for the Pharmacokinetics/Pharmacodynamics (PK/PD) of MUT056399 Ridhi Parasrampuria, Samira M. Garonzik , Alan Forrest , Stefan Fischer , Coralie Soulama-Mouzé , Shankar Lanke , Dung Ngo , Brian Tsuji   PK-PD and mechanistic modeling - Translational applications
Taeshin Park Mechanistic Modeling Approaches in Population PKPD Modeling P. Jasper, J. Tolsma, T.Park, C. Chiang, and L. Li  PDF PK-PD and mechanistic modeling - Other Tools and techniques - Software and algorithms
Chaitali Passey Dosing Equation for Tacrolimus Using Genetic Variants and Clinical Factors by the Population Pharmacokinetics Approach Chaitali Passey, Angela Birnbaum, Richard Brundage, William Oetting, Ajay Israni, Pamala Jacobson   Special populations - Renal or hepatic impairment Clinical applications: therapeutic areas - Immune system Clinical applications: general - Clinical outcomes
Mark Penney Using Mechanistic Modelling of Cyclic Neutropenia to Predict the Effects of a COPD Therapeutic on Systemic Neutrophil Levels Mark Penney and Sophie Stevens  PDF PK-PD and mechanistic modeling - Physiologically-based modeling PK-PD and mechanistic modeling - Systems biology
Venkatesh Pilla Reddy Quantitative Assessment of Olanzapine Exposure-Response Relationship in Acute Schizophrenia using Positive and Negative Syndrome Scale (PANSS) and Comparing its Characteristics across the PANSS Subscales Venkatesh Pilla Reddy, Ahmed Abbas Suleiman, Magdalena Kozielska, Martin Johnson, An Vermeulen, Jing Liu, Rik de Greef , Geny M.M.Groothuis, Meindert Danhof , & Johannes H. Proost.  PDF PK-PD and mechanistic modeling - Exposure response
Venkatesh Pilla Reddy Modeling of Dropout Events and the Reasons for Dropouts in Schizophrenia Clinical Trials Venkatesh Pilla Reddy, Magdalena Kozielska, Ahmed Abbas Suleiman, Martin Johnson, An Vermeulen, Jing Liu, Rik de Greef , Geny M.M.Groothuis, Meindert Danhof , & Johannes H. Proost.  PDF PK-PD and mechanistic modeling - Exposure response Tools and techniques - Missing data
Elodie Plan Performance Comparison of various Maximum Likelihood Nonlinear Mixed-effects Estimation Methods for Pharmacodynamic Models Elodie Plan, Alan Maloney, France Mentré, Mats Karlsson, Julie Bertrand  PDF Tools and techniques - Software and algorithms
Sebastian Polak Combining In Vitro-In Vivo Extrapolation (IVIVE) and Physiologically-Based Pharmacokinetics (PBPK) with Drug Related Risk Assessment: Putting Pieces Together for A Priori Assessment of the Likelihood of Cardiotoxicity Sebastian Polak*, Masoud Jamei, Amin Rostami-Hodjegan   PK-PD and mechanistic modeling - Physiologically-based modeling PK-PD and mechanistic modeling - Translational applications Tools and techniques - Software and algorithms
Bill Poland Viral Dynamics Modeling and Simulation of the HCV Protease Inhibitor MK-7009 (Vaniprevir) with Peg-Interferon and Ribavirin Bill Poland, Luzelena Caro, Michelle Green, Bob Nachbar, Larissa Wenning, Anis Khan, Hamish Wright, Jeff Saltzman, Julie Stone  PDF Clinical applications: therapeutic areas - Antiviral and antimicrobial Clinical applications: general - Disease models
Bill Poland Extending Clinical Utility Analyses to Economic Decision Analyses Bill Poland  PDF Tools and techniques - Decision Analysis
Akshanth R. Polepally Population Pharmacokinetics of Lamotrigine in Pregnant Women Akshanth R. Polepally, Richard C. Brundage, Page B. Pennell, Zachary N. Stowe, D. Jeffrey Newport and Angela K. Birnbaum  PDF Special populations - Pregnancy, maternal/fetal
Daniel G. Polhamus A time to event approach for standard of care meta-analysis in Hepatitis C (HCV) trials. Daniel G. Polhamus*, Kyle T. Baron, Vivek S. Purohit, Patanjali Ravva, James A. Rogers, Marc R. Gastonguay  PDF Tools and techniques - Meta-analysis Tools and techniques - Statistics and biostatistics
Klaas Prins Evaluation of Schild analysis with different modeling approaches to estimate antagonist affinity – a simulation study. Klaas Prins, Piet H. van der Graaf  PDF Tools and techniques - Model evaluation Clinical applications: general - Other preclinical M&S
Ruolun Qiu Clinical Trial Simulation To Assess The Probabilities Of Technical Success For Drugs In Alzheimer's Disease Proof-of-concept Studies Ruolun Qiu, James A Rogers, Brian W Corrigan, Terence Fullerton   Clinical applications: general - Disease models
Angelica L. Quartino A semi-mechanistic model of docetaxel-induced myelosuppression to support dosing recommendation in liver impaired patients Angelica L. Quartino*, Lena E. Friberg, Sharyn D. Baker and Mats O. Karlsson  PDF Clinical applications: therapeutic areas - Oncology
Tonya Quinlan Population Pharmacokinetic/Pharmacodynamic Modeling and Simulations of the Effect of LY2216684 on Heart Rate and the Norepinephrine Metabolite, 3, 4-dihydroxyphenylglycol (DHPG), in Plasma and Cerebrospinal Fluid (CSF) Tonya Quinlan, William Kielbasa  PDF PK-PD and mechanistic modeling - Exposure response
Tonya Quinlan Identification of Optimal Dosing Titration Regimen Using An Adverse Event and Dropout Rate Model Evelyn Lobo, Hanbin Li, Russell Wada, Jaap Mandema   PK-PD and mechanistic modeling - Adverse Event and Dropout Rate Model
Sara Quinney A Semi-mechanistic Pharmacokinetic Model of Midazolam in Pregnancy: Effect of CYP3A Sara Quinney, Mary Hebert, Lang Li  PDF Special populations - Pregnancy, maternal/fetal
Mike Reed Entelos Metabolism PhysioLab® predictions for SGLT2 inhibitor and GLP-1 analog therapies validated by clinical data Mike Reed and Scott Siler  PDF Clinical applications: therapeutic areas - Diabetes
Matthew M. Riggs Application of a Multiscale Physiologically-Based Bone and Calcium Systems Model to Guide the Development of GnRH receptor modulators for the Management of Endometriosis Matthew M. Riggs, Meg Bennetts, Steven W. Martin, Piet H. Van Der Graaf  PDF PK-PD and mechanistic modeling - Physiologically-based modeling PK-PD and mechanistic modeling - Systems biology
Steven P Riley Exposure-Response Model-based Evaluation of Singlet vs Triplicate QTc Measurements in Phase I: Are Triplicates Worth It? Steven P Riley, Jonathan L French, Bojan Lalovic, Marilyn Stolar, Kevin Sweeney, Richard L Lalonde  PDF PK-PD and mechanistic modeling - Exposure response Clinical applications: general - Benefit-risk assessment
Mark Sale Ofatumumab Population Pharmacodynamic Analysis in Patients with Chronic Lymphocytic Leukemia (CLL), Follicular Lymphoma (FL), and Rheumatoid Arthritis (RA) Mark Sale, Roxanne C. Jewell, Bela R. Patel   PK-PD and mechanistic modeling - Exposure response
Mark Sale Ofatumumab Population Pharmacokinetic Analysis in Patients with Chronic Lymphocytic Leukemia (CLL), Follicular Lymphoma (FL), and Rheumatoid Arthritis (RA) Mark Sale, Roxanne C. Jewell, Bela R. Patel   PK-PD and mechanistic modeling - Other
Mark Sale Relationships between metrics reflecting model performance by model within an analysis. Mark Sale, Bruce G. Pollock, Robert R. Bies   Tools and techniques - Model building
Mark Sale Identification of pareto non-dominated sets of NONMEM models using a multi-objective evolutionary algorithm. Mark Sale, Bruce G. Pollock, Robert R. Bies   Tools and techniques - Model building
William Sallas Assessment of published population models for prediction of Phase 3 overall survival in non-small-cell lung cancer patients based on Phase 2 tumor shrinkage William Sallas, Andrew Stein, Wenping Wang, Celine Sarr  PDF Clinical applications: therapeutic areas - Oncology
Mahesh N. Samtani An Improved Model for Disease Progression in Subjects from Alzheimer's Disease Neuroimaging Initiative Mahesh N. Samtani, Michael Farnum, Victor Lobanov, Eric Yang, Nandini Raghavan, Allitia DiBernardo, and Vaibhav Narayan  PPT Clinical applications: general - Disease models
Ramesh Sarangapani Model-based estimation of life-time renal events in diabetic nephropathy patients on aliskiren treatment using short term (6 month) clinical data from AVOID study Sarangapani R., James D., Carter A., Brede Y., Lowy A., and Ebling W.   Clinical applications: general - Disease models
S Sarem Development of Limited Sampling Strategies for Cyclosporine in Pediatric Hematopoietic Stem Cell Transplant Recipients S Sarem, MSc, C Litalien, MD , O Barrière PhD, A-L Lapeyraque, MD, M Duval, MD, P Teira, MD, H Bittencourt, MD, E Haddad, MD, PhD, C De Castelbajac, RN, Y Théorêt, PhD, and F Nekka, PhD.   Tools and techniques - Therapeutic drug monitoring, Limited Sampling Strategies Special populations - Pediatrics
Radojka Savic Disease Progression Model for Multiple Sclerosis and effect of Cladribine Tablets Therapy on Clinical Endpoints Radojka Savic, Alain Munafo, Mats Karlsson   Clinical applications: therapeutic areas - Neurodegenerative diseases
Ryoko Sawamura PK/PD Analysis of Sitagliptin Using a Physiological Glucose-Insulin Model Ryoko Sawamura, Takashi Ito, Ryutaro Nakashima, Masakazu Hirouchi, Tomoko Ishizuka, Noriko Okudaira, Takashi Izumi  PDF PK-PD and mechanistic modeling - Physiologically-based modeling
Ghada F. Ahmed Sawi Population Pharmacokinetics of Unbound and Total Carbamazepine after Simultaneous Oral and Intravenous Dosing in Adults and Elderly Patients Ghada F. Ahmed, Richard C. Brundage, James C. Cloyd, Ilo E. Leppik, James R.Whit, Susan E. Marino, Jeannine M. Conway, John O. Rarick,and Angela K. Birnbaum   Special populations - Geriatrics
Karen Schneck Assessing the Glycemic Response to a Novel Anti-hyperglycemic Agent Using a Semi-mechanistic Integrated Glucose-Insulin Model. Karen Schneck, Xin Zhang, Robert Bauer, Mats Karlsson, Vikram Sinha  PDF PK-PD and mechanistic modeling - Physiologically-based modeling
Corinne Seng Yue Population Pharmacokinetic and Pharmacodynamic Modeling of Acetazolamide in Dialysis Patients and Healthy Volunteers Corinne Seng Yue, Hung H Huynh, Catherine Raymond, Louise Roy   PK-PD and mechanistic modeling - Exposure response Special populations - Renal or hepatic impairment
M. Naveed Shaik A Population Pharmacokinetic (PK)-Pharmacodynamic (PD) Analysis of the Time Course of Neutropenia in Advanced Solid Tumors Patients Treated with PD 0332991 M. Naveed Shaik, Peter O'Dwyer, Gary Schwartz, Patricia M LoRusso, Rachel Courtney, Sophia Randolph , Ana Ruiz-Garcia   PK-PD and mechanistic modeling - Exposure response
Kwang-Hee Shin Population Pharmacokinetics of Ceftazidime in Patients with Automated Peritoneal Dialysis Kwang-Hee Shin*, Kiwon Kim, MD, Kook-Hwan Oh, MD, PhD, Tae-Eun Kim, MD, In-Jin Jang, MD, PhD, Kyung-Sang Yu, MD, PhD   Special populations - Renal or hepatic impairment
Satoshi Shoji Bayesian analysis of the effects of clinically influential covariates for sparse PK data: Use of prior distribution from dense PK data in earlier clinical trials Satoshi Shoji and Shigeyuki Matsui  PDF Tools and techniques - Model building
Indrajeet Singh A Systems Pharmacology Model of Erythropoiesis in Mice Induced by the Small Molecule Inhibitors of Prolyl Hydroxylase Enzymes Indrajeet Singh, Pratap Singh, Wojciech Krzyzanski  PDF PK-PD and mechanistic modeling - Systems biology
Rajendra P. Singh Population Pharmacokinetics and Adverse Event Analysis of Tacrolimus in Pediatric Renal Transplant Recipients Rajendra P. Singh, Sherwin K. Sy, Issa Hazza, Sireen A Shilbayeh, Hartmut Derendorf   PK-PD and mechanistic modeling - Population PK and Adverse event analysis Special populations - Pediatrics
Vikram Sinha Application of An Integrated Glucose-Insulin Pharmacokinetic/Pharmacodynamic Model to Assess Impact of Different Titration Algorithms on Glycemic Control of Rapid Acting Insulin Xiaosu Ma*(1), Leonard Glass, Vikram Sinha   PK-PD and mechanistic modeling - Physiologically-based modeling
Sybil Skinner-Robertson A POPULATION PHARMACOKINETIC MODEL OF ONCE DAILY TRAMADOL IN ELDERLY AND HEALTHY YOUNG VOLUNTEERS Skinner-Robertson S(2)*, Li J, Varin F  GIF Special populations - Geriatrics
Mike K Smith Hemodynamics as an Additional Measure to Prove Efficacy and to Provide a Dose Rationale for Sildenafil in Pediatric Patients With Pulmonary Arterial Hypertension (PAH) Mike K Smith, Lutz Harnisch, Pascal Chanu, Xiang Gao, Rene Bruno   Special populations - Pediatrics
SaeHeum Song Olmesartan medoxomil dosing schedule justification in pediatric hypertensive patients.. SaeHeum Song*, Raymond Miller, Daniel Salazar  PPT Special populations - Pediatrics
Mary E. Spilker Mathematical Characterization of the DNA Damage Response to Gemcitabine and a Chk1 Inhibitor. Mary E. Spilker, Xiaolin Kang, Erick Kindt, and Shinji Yamazaki   PK-PD and mechanistic modeling - Exposure response
Jasper Stevens Preclinical mechanism-based PK-PD model of remoxipride with rat-to-human extrapolation: characterizing remoxipride target site PK and systems homeostatic feedback Jasper Stevens, Bart Ploeger, Piet H van der Graaf, Meindert Danhof, Elizabeth CM de Lange  PPT PK-PD and mechanistic modeling - Translational applications
Sophie Stocker POPULATION PHARMACOKINETIC OF OXYPURINOL IN PATIENTS WITH GOUT RECEIVING ALLOPURINOL Sophie Stocker*, Andrew McLachlan, Radojka Savic, Carl Kirkpatrick, Ken Williams, Ric Day  PDF Clinical applications: general - Clinical pharmacokinetics
Julie A. Stone A Semi-mechanistic Approach to PK/PD Modeling of Complex Response Data: Bone Turnover Example for Odanacatib, a Cathepsin K Inhibitor Julie A. Stone*, Stefan Zajic, David Jaworowicz, Albert Leung, Le Thi Duong, Julie Passarell, Jill Fiedler-Kelly, Dosinda Cohn, Nadia Verbruggen, and Aubrey Stoch   PK-PD and mechanistic modeling - Exposure response Tools and techniques - Model building
Herbert Struemper Physiologically-based modeling of recombinant human IL-18 pharmacokinetics Herbert Struemper*, Kevin M. Koch, John Bauman, Michael J. Robertson, John F. Toso  PDF PK-PD and mechanistic modeling - Physiologically-based modeling
Kulandayan Subramanian Modeling of drug-target binding for an antibody targeting a rapid turnover chemokine Kulandayan Subramanian, Sherri Dudal, Andrej Skerjanec, Frank Brennan, Peter Lloyd, Phil Lowe  PDF PK-PD and mechanistic modeling - Exposure response
Liviawati Sutjandra Population Pharmacokinetic Analysis of Denosumab in Advanced Cancer Patients with Solid Tumors Leonid Gibiansky, Liviawati Sutjandra, Sameer Doshi, Jenny Zheng, Winnie Sohn, Mark Peterson, Graham Jang, Andrew Chow, Juan Jose Perez Ruixo   Clinical applications: general - Clinical pharmacokinetics
Brinda Tammara Exposure-Response Relationships with Respect to Events of Nausea and Vomiting of PF-xxx, a Novel Oxyntomodulin Analogue, in Healthy Obese Subjects. Brinda Tammara, Chandra Udata   PK-PD and mechanistic modeling - Exposure response
Michael A. Tortorici A Population Pharmacokinetic (PK)–Pharmacodynamic (PD) Analysis of the Time Course of Tumor Shrinkage by Axitinib in Patients with Metastatic Colorectal Cancer (mCRC) Michael A. Tortorici, Jeffrey Infante, Jamal Tarazi, Alejandro Ricart, Thomas Cartwright, Johanna C. Bendell, and Ana Ruiz-Garcia   Clinical applications: therapeutic areas - Oncology
Pavan K. Vaddady In Vivo Pharmacokinetic-In Vitro Pharmacodynamic Approach to Optimize Dosing Regimen of Lee1445, a Novel Spectinamide Anti-Tuberculosis Agent Pavan K. Vaddady, Josiah T. Ryman, Richard E. Lee, Bernd Meibohm   PK-PD and mechanistic modeling - Translational applications Clinical applications: therapeutic areas - Antiviral and antimicrobial
J.G. Coen van Hasselt Semi-physiological population PK-PD model for eribulin associated neutropenia J.G. Coen van Hasselt, Anubha Gupta, Ziad Hussein, Larisa Reyderman, Jantien Wanders, Jos H. Beijnen, Jan H.M. Schellens, Alwin D.R. Huitema   Clinical applications: therapeutic areas - Oncology
Scott Van Wart Modeling the Time-Course of Body Weight for Subjects Given Placebo in an Obesity Trial Scott Van Wart, Max Tsai, Jean Chan, Brenda B. Cirincione   Clinical applications: general - Disease models
Scott A. Van Wart A Pooled-Analysis Approach to Develop a Population Pharmacokinetic (PK) Model for Furosemide Scott A. Van Wart, Suresh Mallikaarjun, Susan Shoaf, Donald E. Mager   Tools and techniques - Meta-analysis Clinical applications: therapeutic areas - Heart failure
Paolo Vicini Towards Modeling and Simulation of Immune Responses in Vivo: An Integrated Model of Cellular and Humoral Responses Paolo Vicini*, Sirus Palsson, Timothy Hickling, Erica Pierce, Michael Zager, Karin Jooss, Peter O'Brien, Mary E. Spilker, Scott Fountain and Bernhard O. Palsson   PK-PD and mechanistic modeling - Systems biology
Russell Wada Meta-analysis of Kaplan-Meier overall survival curves from selected randomized controlled Phase II/III trials in advanced melanoma R Wada, Y Feng, N Zhang, A Roy, M Pfister, K Chin, A Hoos, P Mukhopadhyay, TT Chen, E Masson  PDF Tools and techniques - Meta-analysis Clinical applications: therapeutic areas - Oncology
Timothy Waterhouse Design of a Phase 2 Clinical Trial for a Combination Therapy with Sparse Sampling in which Drug-Drug Interactions are Assessed Timothy Waterhouse, Cheng Cai Tang, Charles Benson, Nita Patel  PDF Tools and techniques - Experiment design
Susan Willavize Mixture Modeling as a Data Imputation Method Susan Willavize*, Jill Fiedler-Kelly, William Hanley, Lisa Mahnke, Yaming Hang, Zhuoying-Joanna Peng, Luann Phillips   Tools and techniques - Missing data
Shu-Pei Wu Interspecies Pharmacokinetic Scaling of Dasatinib – an Application of Nonlinear Mixed Effects Modeling Shu-Pei Wu and Rose Feng  PDF PK-PD and mechanistic modeling - Exposure response
Yan Xin Simultaneous Modeling of MNRP1685A Pharmacokinetics and its Circulating Target in Cynomolgus Monkeys Using Two-Target Quasi-Steady-State (QSS) Model Yan Xin*, Hong Xiang, Denise Jin, John Lowe, Yanmei Lu, Rashell Kinard, Mauricio Maia, Y. Gloria Meng, Shuang Bai  PDF PK-PD and mechanistic modeling - Physiologically-based modeling
Hongmei Xu Mechanism-based Modeling of Growth and Killing of Pseudomonas aeruginosa by Polymyxin B and Aztreonam in Monotherapy or Sequential Combination Therapy Hongmei Xu, Brian T Tsuji, Silvia V Brown, Rebecca E. D'Hondt, Alan Forrest, Jürgen B Bulitta   PK-PD and mechanistic modeling - Systems biology
Bai Xue A Method to Define a Single Optimal Sampling Strategy for Three Drugs (Delafloxacin, Linezolid, and Vancomycin) to Facilitate PK-PD Analyses in a Blinded, Phase 2 Study Bai Xue, Ridhi Parasrampuria, Christopher Rubino, Eric Burak, Alan Forrest  PDF Clinical applications: general - Study design/conduct
Bai Xue Population Pharmacokinetic Analysis and Design of an Optimal Sampling Strategy for Clopidogrel Bai Xue, Murad Melhem, Daniel K. Reynolds, Al-Motassem Yousef, Scott A. Van Wart  PDF Clinical applications: general - Study design/conduct
Xiaoyu Yan Population Pharmacokinetic and Pharmacodynamic Model of Pharmacodynamics-Mediated Drug Disposition (PDMDD) of Erythropoiesis Stimulating Agent Xiaoyu Yan, Phil Lowe, Etienne Pigeolet, Martin Fink, Alexander Berghout, Sigrid Balser, Wojciech Krzyzanski  PDF Clinical applications: general - Clinical pharmacokinetics
Bei Yang Interspecies Scaling and Pharmacokinetics of WR-1065 in Animals and Humans Using Nonlinear Mixed Effects Modeling Bei Yang, Rose Feng, Zheng Lu, and David E Smith   PK-PD and mechanistic modeling - Exposure response
Zhenling Yao Population Pharmacokinetic-Pharmacodynamic Modeling to Support Biocomparability Assessment of Moxetumomab Pasudotox in Cynomolgus Monkeys Yao*, Lorin Roskos, Mikhail Zusmanovich, Meina Liang, Theresa LaVallee, Bing Wang  PPT PK-PD and mechanistic modeling - Physiologically-based modeling
Ka Lai Yee Determination of the Relative Sensitivity of the Exposure Response Relationship for Subjective Alertness and WASO in Healthy Volunteers Ka Lai Yee, Itay Perlstein, Xiaodong Li, Hong Sun   PK-PD and mechanistic modeling - Exposure response PK-PD and mechanistic modeling - Translational applications
Jing Yu Population PK modeling incorporating enzyme induction mechanism to guide the design of optimal dose regimen for an antiviral drug Jing Yu, June Ke, Leo Kawai  PDF Clinical applications: therapeutic areas - Antiviral and antimicrobial
Jingyu Yu A Pulmonary PBPK model to Predict the Pharmacokinetics of Inhaled Drugs in Airways and Alveoli Jingyu Yu*, Xinyuan Zhang, Andrew Schrotenboer, Kathleen A. Stringer, Gus R. Rosania  PDF PK-PD and mechanistic modeling - Physiologically-based modeling PK-PD and mechanistic modeling - Systems biology Tools and techniques - Experiment design
A. Yin Zhang Population Pharmacokinetics Modeling of Melatonin and Correlations to Sleep Outcome Metrics in Elderly with Melatonin Deficiency and Insomnia A. Yin Zhang, Nalaka Gooneratne, Jeffrey Barrett   Special populations - Geriatrics
Xin Zhang Optimal Dose Selection for a Novel Glucokinase Activator Using a Semi-mechanistic Integrated Glucose-Insulin Model Xin Zhang, Karen Schneck, Michael Heathman, Juliana Bue-Valleskey, Steve Waters, Vikram Sinha   PK-PD and mechanistic modeling - Physiologically-based modeling Clinical applications: therapeutic areas - Diabetes
Baiteng Zhao Physiologically-Based Pharmacokinetic Modeling of an Anti-CD70 Auristatin Antibody-Drug Conjugate in Tumor-Bearing Mice Baiteng Zhao*(1), Songmao Zheng(2), Stephen C. Alley(1)   PK-PD and mechanistic modeling - Physiologically-based modeling
Huafeng Zhou An Evaluation of Posterior Predictive Check (PPC) in Diagnosing Population PK Models Zifang Guo, Huafeng Zhou, Yaming Hang, Kuenhi Tsai   Tools and techniques - Model evaluation
Min Zhu Establish a Model System for Evaluation of Drug Interaction in Oncology: Paclitaxel Example Min Zhu, E Niclas Jonsson, Cheng-Peng Hsu and Yu-Nien Sun  PDF Clinical applications: therapeutic areas - Oncology
Yali Zhu Dosing Strategy Investigation for a Cyclin Dependent Kinase (CDK) Inhibitor using a Population Pharmacokinetics Approach Da Zhang , Yali Zhu , Pratapa Prasad , Paul Statkevich  PDF Clinical applications: therapeutic areas - Oncology
Jochen Zisowsky Population PK/PD analyses of CONSCIOUS-2, a study with clazosentan to reduce vasospasm-related morbidity and all-cause mortality in adult patients with aneurysmal subarachnoid hemorrhage. Jochen Zisowsky, Eliane Fuseau, Shirin Bruderer, Marcelo Gutierrez, Andreas Krause, Jasper Dingemanse  PDF Clinical applications: therapeutic areas - Other therapeutic area
Peiying Zuo A Population Pharmacokinetic Model for Ondansetron in Pediatric and Adult Patients Peiying Zuo*, Virginia Schmith, Lynda Haberer, Malcolm Young  PDF Special populations - Pediatrics
Peiying Zuo Mechanistic physiologically-based model to determine mechanism of action of a diabetic agent and optimize clinical trial design Peiying Zuo*, Brian G Topp, Steven B Waters, Lakshmi S Vasist, Malcolm A Young, Michael J Reed, Richard V Clark  PDF PK-PD and mechanistic modeling - Physiologically-based modeling

 

Narayan Cheruvu (Covidien), Xiaohua Gong (Glaxo SmithKline) and Alena Yin Zhang